Insight Molecular Diagnostics shareholders approve 1.75M share equity plan increase
At its June 11, 2026 annual meeting, Insight Molecular Diagnostics shareholders approved an amendment adding 1,750,000 shares to its equity incentive plan, bringing the total authorized to 5,550,000 shares. All four director nominees were re-elected, and the shareholders also ratified CBIZ CPAs P.C. as auditor and approved executive pay on an advisory basis. The filing reports routine annual meeting outcomes and does not describe any change in leadership or finances.
Key points
- Plan amendment approved: 19,117,865 votes for, 122,829 against, 4,799 abstained
- Total shares authorized under the Incentive Plan rises to 5,550,000 from 3,800,000 (1,750,000 added)
- Four directors elected to serve until the 2027 annual meeting: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.